Literature DB >> 27000509

Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy.

Frank Kimsey1, Jesse McKay1, Jeffrey Gefter1, Michael T Milano2, Vitali Moiseenko3, Jimm Grimm4, Ronald Berg1.   

Abstract

Many recent studies have described rib fractures and chest wall pain following stereotactic body radiation therapy (SBRT). Although these toxicities generally are not life-threatening, the chest wall and ribs are considered dose-limiting tissues because of the potential effect on patients׳ quality of life. Few studies have reported dose-response models that can provide quantitative estimates of risk as a function of dose and volume. Notably, Memorial Sloan Kettering Cancer Center (Mutter et al(8)) analyzed grade 2 or higher chest wall toxicity in a cohort of 126 patients treated with linear accelerator-based SBRT; the authors provided detailed dose-volume histogram (DVH) data to allow for pooled analyses. We pooled these 126 patients with an additional 44 patients treated with CyberKnife at the Erlanger Medical Center to create an updated dose-response model for chest wall tolerance. In the aggregate analysis, the 10% risk level for grade 2 or higher complications for D70cc was 16.2Gy in 4 fractions, and the 50% risk level was D70cc = 65.1Gy in 4 fractions. For D2cc, the 10% and 50% risk levels in 4 fractions were 43.0Gy and 87.9Gy, respectively. These dose-tolerance limits may help quantify chest wall toxicity risks. Further research continues to determine more accurate estimates of grade 3 risk levels.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 27000509     DOI: 10.1016/j.semradonc.2015.11.003

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  9 in total

1.  Characterization of Chest Wall Toxicity During Long-term Follow Up After Thoracic Stereotactic Body Radiation Therapy.

Authors:  Christopher Chipko; Julius Ojwang; Leila Rezai Gharai; Xiaoyan Deng; Nitai Mukhopadhyay; Elisabeth Weiss
Journal:  Pract Radiat Oncol       Date:  2019-02-04

Review 2.  GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer.

Authors:  Núria Rodríguez De Dios; Arturo Navarro-Martin; Cristina Cigarral; Rodolfo Chicas-Sett; Rafael García; Virginia Garcia; Jose Antonio Gonzalez; Susana Gonzalo; Mauricio Murcia-Mejía; Rogelio Robaina; Amalia Sotoca; Carmen Vallejo; German Valtueña; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-04-24

Review 3.  Doses, fractionations, constraints for stereotactic radiotherapy.

Authors:  Simona Borghesi; Cynthia Aristei; Francesco Marampon
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

Review 4.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

5.  Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors.

Authors:  Younghee Park; Hee Jung Kim; Ah Ram Chang
Journal:  Radiat Oncol       Date:  2017-04-05       Impact factor: 3.481

6.  Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.

Authors:  Anand Mahadevan; Bahman Emami; Jimm Grimm; Lawrence R Kleinberg; Kristin J Redmond; James S Welsh; Robert Rostock; Eric Kemmerer; Kenneth M Forster; Jason Stanford; Sunjay Shah; Sucha O Asbell; Tamara A LaCouture; Carla Scofield; Ian Butterwick; Jinyu Xue; Alexander Muacevic; John R Adler
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

Review 7.  Stereotactic radiotherapy for lung oligometastases.

Authors:  Lorenzo Falcinelli; Claudia Menichelli; Franco Casamassima; Cynthia Aristei; Simona Borghesi; Gianluca Ingrosso; Lorena Draghini; Angiolo Tagliagambe; Serena Badellino; Michela Buglione di Monale E Bastia
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

8.  Estimating the tolerance of brachial plexus to hypofractionated stereotactic body radiotherapy: a modelling-based approach from clinical experience.

Authors:  Irina Kapitanova; Sharmi Biswas; Sabrina Divekar; Eric J Kemmerer; Robert A Rostock; Kenneth M Forster; Rachel J Grimm; Carla J Scofield; Jimm Grimm; Bahman Emami; Anand Mahadevan
Journal:  Radiat Oncol       Date:  2021-06-07       Impact factor: 3.481

9.  Exploratory analysis using machine learning to predict for chest wall pain in patients with stage I non-small-cell lung cancer treated with stereotactic body radiation therapy.

Authors:  Hann-Hsiang Chao; Gilmer Valdes; Jose M Luna; Marina Heskel; Abigail T Berman; Timothy D Solberg; Charles B Simone
Journal:  J Appl Clin Med Phys       Date:  2018-07-10       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.